Candida Antigen and Bivalent HPV Vaccine in the Treatment of Multiple Warts
Launched by ZAGAZIG UNIVERSITY · Mar 14, 2022
Trial Information
Current as of July 24, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new treatment for common warts, which are caused by the Human Papilloma Virus (HPV). Researchers want to find out if a combination of a Candida antigen and a bivalent HPV vaccine can help treat warts more effectively. The trial is currently looking for participants of all genders, aged 32 to 87, who have multiple warts that have not responded well to previous treatments.
If you join the study, you will receive either the new treatment or a combination of treatments, and the researchers will monitor how well it works and if there are any side effects. To be eligible, you should not be pregnant and must not have an allergy to either the Candida antigen or the HPV vaccine. This trial aims to provide a better option for people struggling with persistent warts, and your participation could contribute to important medical knowledge.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • patients with multiple, recalcitrant, or non-recalcitrant common warts of different sites, sizes, duration, and with or without distant lesions will be enrolled in the study
- Exclusion Criteria:
- • Pregnant female. Hypersensitivity to Candida antigen or bivalent HPV vaccine
About Zagazig University
Zagazig University, a prominent educational and research institution located in Egypt, plays a pivotal role in advancing medical knowledge and promoting health innovations through its clinical trials. With a commitment to excellence in research, the university leverages its diverse expertise and state-of-the-art facilities to conduct rigorous clinical studies that aim to improve patient care and outcomes. By fostering collaboration among multidisciplinary teams, Zagazig University contributes significantly to the global medical community, ensuring that its clinical trials adhere to the highest ethical standards and regulatory requirements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Zagazig, Al Sharqia, Egypt
Patients applied
Trial Officials
Reham Essam, MD
Principal Investigator
Zagazig University
Ahmad Nofal, MD
Study Director
Zagazig University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials